<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550794</url>
  </required_header>
  <id_info>
    <org_study_id>2018P-000204</org_study_id>
    <nct_id>NCT03550794</nct_id>
  </id_info>
  <brief_title>Thiamine as a Renal Protective Agent in Septic Shock</brief_title>
  <official_title>Thiamine as a Renal Protective Agent in Septic Shock: A Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo controlled study to investigate the effect of
      intravenous thiamine (vitamin B1) on renal function in septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled study to investigate the effect of
      intravenous thiamine (vitamin B1) on renal injury in septic shock. Patients admitted with
      septic shock who have a lactate of at least 2.0mmol/L and do not have pre-existing renal
      failure requiring dialysis will be eligible for the study. Enrolled patients will be
      randomized to intravenous thiamine 200mg twice daily for 6 doses or matching placebo. Blood
      will be drawn at several time points to assess biomarkers of renal injury. Secondary
      endpoints include need for renal replacement therapy, length of ICU stay, and hospital
      mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A randomization list will be prepared by an independent statistician using 1:1 randomization in blocks of two and four. This list will be provided to the research pharmacy, and the research pharmacy will be the only unblinded people involved with the study, and will have no patient contact or role in the analysis or other aspects of the study. Thiamine is colorless and odorless, and the 200mg dose is mixed in 5mL of normal saline. Placebo will be 50mL of normal saline and is indistinguishable in appearance from thiamine. Study team, clinical team and patient and family will all be blind to the allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney injury biomarker</measure>
    <time_frame>Enrollment to 72-hours</time_frame>
    <description>Change in creatinine over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>From date of enrollment until discharge from the intensive care unit (ICU) or date of death, whichever comes first, up to 60 days after enrollment</time_frame>
    <description>Need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>From date of enrollment until discharge from the intensive care unit (ICU) or date of death, whichever comes first, up to 60 days after enrollment</time_frame>
    <description>Length of ICU stay truncated at 60 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>From date of enrollment until discharge from the hospital or date of death, whichever comes first, up to 60 days after enrollment</time_frame>
    <description>Length of hospital stay truncated at 60 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Sepsis</condition>
  <condition>Kidney Injury</condition>
  <condition>Thiamine Deficiency</condition>
  <arm_group>
    <arm_group_label>Thiamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiamine Hydrochloride</intervention_name>
    <description>Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.</description>
    <arm_group_label>Thiamine</arm_group_label>
    <other_name>Thiamine</other_name>
    <other_name>Vitamin B1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50ml of 0.9% NACL will serve as the placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>0.9%NACL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult ≥18 years of age

          2. Suspected or Confirmed Infection (defined as collection of a blood/fluid culture and
             provision of an antimicrobial)

          3. Receipt of a vasopressor agent (e.g. norepinephrine, phenylephrine, vasopressin)

          4. Serum lactate ≥2mmol/L

          5. Creatinine &gt;1.0mg/dL

        Exclusion Criteria:

          1. Clinical indication for thiamine administration (alcoholism, known or highly suspected
             deficiency) or treatment with thiamine beyond the amount found in a standard
             multivitamin within the last 10 days

          2. Renal replacement therapy within the past 30 days

          3. Comfort measures only or anticipated withdrawal of support within 24 hours

          4. Protected populations (pregnant women, prisoners)

          5. Known thiamine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Moskowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari Moskowitz, MD</last_name>
    <phone>6177543464</phone>
    <email>amoskowi@bidmc.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Donnino, MD</last_name>
    <phone>6177543463</phone>
    <email>mdonnino@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Moskowitz, MD</last_name>
      <phone>617-754-5864</phone>
      <email>amoskowi@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northshore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Gong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Hospital</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Gong, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial. Ann Am Thorac Soc. 2017 May;14(5):737-741. doi: 10.1513/AnnalsATS.201608-656BC.</citation>
    <PMID>28207287</PMID>
  </reference>
  <reference>
    <citation>Donnino MW, Andersen LW, Chase M, Berg KM, Tidswell M, Giberson T, Wolfe R, Moskowitz A, Smithline H, Ngo L, Cocchi MN; Center for Resuscitation Science Research Group. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med. 2016 Feb;44(2):360-7. doi: 10.1097/CCM.0000000000001572.</citation>
    <PMID>26771781</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Ari Moskowitz</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine Deficiency</mesh_term>
    <mesh_term>Beriberi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

